protein

MAP

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about MAP: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

91Connections

23Hypotheses

3Analyses

50Outgoing

36Incoming

2Experiments

5Debates

Summary

DUSP6 (also known as MKP3) is a dual-specificity phosphatase that specifically dephosphorylates and inactivates ERK1/2. It functions as a negative regulator of MAPK signaling and has been implicated in neurodegenerative diseases including Parkinson's disease.

View on Wiki →

No AI portrait yet

🔬 Protein Info

Gene Symbol	MAP
Aliases	also known as MKP3
Molecular Weight	39.8 kDa
Pathways	pathway: [@dusp6_erk2019], MAPK pathway, MAPK, MAPK Signaling
GeneCards	MAP
Human Protein Atlas	MAP
Associated Diseases	ALS, Alzheimer, Alzheimer's disease, neurodegeneration, neuroinflammation, Parkinson
Interactions	ALZHEIMER, BDNF, CD33, CD44, CDK5, CX3CL1
KG Connections	91 knowledge graph edges
Databases	GeneCards UniProt NCBI Gene HPA STRING

Wiki Pages (21)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

graph TD
    MAP["MAP"]
    CD33(["CD33"])
    MAP -->|"activates"| CD33
    P2RY1(["P2RY1"])
    MAP -->|"co_discussed"| P2RY1
    P2RY12(["P2RY12"])
    MAP -->|"activates"| P2RY12
    CD44(["CD44"])
    MAP -->|"activates"| CD44
    NEURON(["NEURON"])
    MAP -->|"co_discussed"| NEURON
    WAS(["WAS"])
    MAP -->|"co_discussed"| WAS
    ALZHEIMER(["ALZHEIMER"])
    ALZHEIMER -->|"interacts_with"| MAP
    GENES(["GENES"])
    GENES -->|"co_discussed"| MAP
    HCRTR1(["HCRTR1"])
    HCRTR1 -->|"co_discussed"| MAP
    HCRTR2(["HCRTR2"])
    HCRTR2 -->|"interacts_with"| MAP
    style MAP fill:#1a3a4a,stroke:#4fc3f7,stroke-width:3px,color:#4fc3f7

Outgoing (55)

Target	Relation	Type	Str
MAPK signaling	participates_in	pathway	0.80
neuroinflammation	activates	disease	0.80
PGAM5	associated_with	gene	0.60
PINK1	associated_with	gene	0.60
NF-kB signaling	participates_in	pathway	0.60
Alzheimer's disease	causes	disease	0.60
TGF-beta signaling	participates_in	pathway	0.60
oligodendrocytes	expressed_in	cell_type	0.60
neurodegeneration	activates	disease	0.60
Wnt signaling	participates_in	pathway	0.60
ALS	associated_with	disease	0.60
epigenetic regulation	participates_in	pathway	0.60
TNF	activates	gene	0.60
synaptic plasticity	participates_in	pathway	0.60
ROS	regulates	gene	0.60
MLKL	activates	gene	0.60
autophagy pathway	participates_in	pathway	0.60
Alzheimer	associated_with	disease	0.60
Parkinson	associated_with	disease	0.60
neurodegeneration	associated_with	disease	0.60
neuroinflammation	causes	disease	0.60
PS1	associated_with	gene	0.60
RIPK2	expressed_in	gene	0.60
UHRF1	expressed_in	gene	0.60
necroptosis	participates_in	pathway	0.60
Alzheimer's disease	inhibits	disease	0.60
VGLUT1	inhibits	gene	0.60
ubiquitin-proteasome	participates_in	pathway	0.60
P38	activates	gene	0.60
TNF	targets	gene	0.60
PTEN	regulates	gene	0.60
apoptosis pathway	participates_in	pathway	0.60
oxidative stress response	participates_in	pathway	0.60
MAPK	expressed_in	gene	0.60
MAPK7	expressed_in	gene	0.60
MRPS31	expressed_in	gene	0.60
astrocytes	expressed_in	cell_type	0.55
microglia	expressed_in	cell_type	0.55
neurons	expressed_in	cell_type	0.55
MAP6	associated_with	gene	0.55
MAP2	regulates	gene	0.55
insulin signaling	participates_in	pathway	0.55
DYSTROPHIN	inhibits	protein	0.50
PINK1	co_expressed_with	gene	0.50
PTEN	co_expressed_with	gene	0.50
GAD1	inhibits	gene	0.50
WAS	regulates	protein	0.50
MAPK	co_expressed_with	gene	0.50
STING	co_discussed	gene	0.50
WAS	co_discussed	protein	0.50

Incoming (36)

Source	Relation	Type	Str
GRID2	expressed_in	gene	0.60
E2F2	expressed_in	gene	0.60
ELAVL1	expressed_in	gene	0.60
G6PD	expressed_in	gene	0.60
APP	associated_with	gene	0.60
GFAP	associated_with	gene	0.60
BDNF	inhibits	gene	0.60
ATM	regulates	gene	0.60
ABCA7	expressed_in	gene	0.60
ARF1	expressed_in	gene	0.60
ATG7	expressed_in	gene	0.60
CDK5	activates	gene	0.60
ERK1	activates	gene	0.60
GSK3	activates	gene	0.60
DNA	regulates	gene	0.60
JNK1	activates	gene	0.60
JNK2	activates	gene	0.60
HCRTR1	biomarker_for	gene	0.60
HCRTR2	biomarker_for	gene	0.60
HCRTR1	interacts_with	gene	0.60
AKT	associated_with	gene	0.60
ERK	associated_with	gene	0.60
CX3CL1	activates	gene	0.60
CX3CR1	activates	gene	0.60
LOX	associated_with	gene	0.60
MAO	associated_with	gene	0.60
JNK1	co_expressed_with	gene	0.50
JNK2	co_expressed_with	gene	0.50
ALZHEIMER	interacts_with	gene	0.50
HCRTR1	co_discussed	gene	0.50
HCRTR2	interacts_with	gene	0.50
CBL	co_expressed_with	gene	0.50
GENES	co_discussed	gene	0.50
ERK	co_expressed_with	protein	0.50
BCL2	co_expressed_with	gene	0.50
BNIP3	co_expressed_with	gene	0.50

Targeting Hypotheses (23)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
MAPT tau seeding and release across AD, FTD, and PD-spectrum	0.812	multi	Cross-disease neurodegeneration mechanis
Tau/MAP6 ratio as a master switch for microtubule dynamics p	0.750	neurodegeneration	-
MAP6-CRMPS cooperative phosphorylation by GSK3β	0.700	neurodegeneration	-
Excitatory Neuron Synaptic Dysfunction and Mitochondrial Str	0.660	neurodegeneration	Cell type vulnerability debate in Alzhei
Tau/MAP6 antagonism in neurodegeneration progression	0.650	neurodegeneration	-

DLK MAPK Pathway Inhibition to Block Tau-Induced Neurotoxici	0.634	neurodegeneration	Should microtubule-stabilizing drugs be
Rutin stabilizes a non-nucleating tau conformer through dire	0.627	neurodegeneration	What is the molecular mechanism by which
Selective p38γ MAPK Inhibition Reduces Pathological Tau Phos	0.625	neurodegeneration	Test
ATF4-DDIT3 stress signaling indirectly represses MAPT transc	0.624	neurodegeneration	Which specific transcription factors med
Activity-dependent MAP6 scaffolding at synapses	0.600	neurodegeneration	-
HSF1 reprioritizes transcription and suppresses MAPT while r	0.598	neurodegeneration	Which specific transcription factors med
Tau-Independent Microtubule Stabilization via MAP6 Enhanceme	0.567	neurodegeneration	Selective vulnerability of entorhinal co
Developmental stage-specific dominance of tau vs MAP6 functi	0.550	neurodegeneration	-
REST-like neuronal silencing programs suppress MAPT in sever	0.506	neurodegeneration	Which specific transcription factors med
MAP6-mediated microtubule stabilization as therapeutic targe	0.500	neurodegeneration	-
CX3CR1 PET with Nano-bodies for Microglial Surveillance Stat	0.477	biomarkers	What biomarkers can reliably detect micr
Astrocyte CD38-erk Mapk signaling controls mitochondrial tra	0.380	als-and-alzheimers	Mitochondrial transfer between neurons a
AD fine-mapping identifies causal variants in microglia-spec	0.380	alzheimers	Statistical Fine-Mapping of AD GWAS Loci
CREB-Mediated Differential CD55/CD46 Expression Creates Acti	0.380	synaptic-biology	What determines the selectivity of compl
CREB-Mediated Differential CD55/CD46 Expression Creates Acti	0.380	synaptic-biology	What determines the selectivity of compl
Concrete Development Roadmap and Final Position	0.000	-	-
MAPT Transcriptional Control	0.000	-	4R-tau strain-specific spreading pattern
Neuronal MAPT-Vulnerability Stratified Therapy	0.000	-	Cell type vulnerability in Alzheimer's D

Mentioning Analyses (3)

Scientific analyses that reference this entity

Which specific transcription factors mediate MAPT suppression during proteostati

neurodegeneration | 2026-04-25 | 3 hypotheses Top: 0.624

Proteomics Differential Expression in AD CSF and Brain Tissue

neurodegeneration | 2026-04-16 | 1 hypotheses Top: 0.865

Cas13 gRNA Design for Silencing MAPT (Tau) Transcripts in Alzheimer's Disease

neurodegeneration | 2026-04-16 | 0 hypotheses

Experiments (2)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
iPSC-derived astrocyte-neuron co-culture mitochondrial transfer in PD	exploratory	Parkinson's disease	0.900	0.00	iPSC-derived dopaminergic neur	proposed	N/A
Autophagy receptor identification for stress granule elimination	exploratory	neurodegenerative diseases	0.900	0.00	cultured cells under arsenite	proposed	N/A

Related Papers (11)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year
Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810]	["Chen Kai", "Li Fuyao", "Zhang Shuwen",	Journal of neuroinflammation	2025
Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810]	["Chen Kai", "Li Fuyao", "Zhang Shuwen",	Journal of neuroinflammation	2025
P-tau217 correlates with neurodegeneration in Alzheimer's disease, and targeting [PMID:38513667]	Zhang D, Zhang W, Ming C, Gao X, Yuan H,	Neuron	2024
Neurodegeneration and Inflammation-An Interesting Interplay in Parkinson's Disea [PMID:33182554]	Marogianni C, Sokratous M, Dardiotis E,	International journal of molec	2020
Neurodegeneration and Inflammation-An Interesting Interplay in Parkinson's Disea [PMID:33182554]	Marogianni C, Sokratous M, Dardiotis E,	International journal of molec	2020
Tau protein aggregation is associated with cellular senescence in the brain. [PMID:30126037]	["Musi Nicolas", "Valentine Joseph M", "	Aging cell	2018
Multiple Sclerosis Pathology. [PMID:29358320]	Lassmann H	Cold Spring Harbor perspective	2018
Tau protein aggregation is associated with cellular senescence in the brain. [PMID:30126037]	["Musi Nicolas", "Valentine Joseph M", "	Aging cell	2018
LRRK2 Promotes Tau Accumulation, Aggregation and Release. [PMID:26014385]	Unknown	Molecular neurobiology	2017
Etiology and pathophysiology of frontotemporal dementia, Parkinson disease and A [PMID:18322368]	Unknown	Neuro-degenerative diseases	2008
The role of tau (MAPT) in frontotemporal dementia and related tauopathies. [PMID:15365985]	Unknown	Human mutation	2005

Debates (5)

Multi-agent debates referencing this entity

Which specific transcription factors mediate MAPT suppression during proteostati

closed · Rounds: 4 · Score: 0.66 · 2026-04-25

Can optimized Cas13 guide RNAs selectively silence pathogenic MAPT splice varian

closed · Rounds: 4 · Score: 0.70 · 2026-04-21

Which proteins are differentially expressed in AD CSF and brain tissue, and do t

closed · Rounds: 4 · Score: 0.70 · 2026-04-21

Is a 12-protein CSF panel superior to existing plasma p-tau217 for clinical AD p

closed · Rounds: 4 · Score: 0.70 · 2026-04-16

Is Cas13-based 4R-tau silencing feasible given collateral cleavage risks in post

closed · Rounds: 4 · Score: 0.70 · 2026-04-16

Related Research

Hypotheses and analyses mentioning MAP in their description or question text

MAP

Understanding Entity Pages

Summary

Wiki Pages (21)

Cerebral Autoregulation in Neurodegeneration

BIIB080 (MAPTRx) Antisense Oligonucleotide for Alzheimer's Disease

MAPK9 Gene

MAPK/ERK Signaling Pathway in Neurodegeneration

MAP1LC3A Gene

MAPT→Tau→Aggregation→PSP Causal Chain

Pathway Diagram

Outgoing (55)

Incoming (36)

Targeting Hypotheses (23)

Mentioning Analyses (3)

Which specific transcription factors mediate MAPT suppression during proteostati

Proteomics Differential Expression in AD CSF and Brain Tissue

Cas13 gRNA Design for Silencing MAPT (Tau) Transcripts in Alzheimer's Disease

Experiments (2)

Related Papers (11)

Debates (5)

Which specific transcription factors mediate MAPT suppression during proteostati

Can optimized Cas13 guide RNAs selectively silence pathogenic MAPT splice varian

Which proteins are differentially expressed in AD CSF and brain tissue, and do t

Is a 12-protein CSF panel superior to existing plasma p-tau217 for clinical AD p

Is Cas13-based 4R-tau silencing feasible given collateral cleavage risks in post

Related Research

DLK MAPK Pathway Inhibition to Block Tau-Induced Neurotoxicity Without Directly

Rutin stabilizes a non-nucleating tau conformer through direct MAPT repeat-domai

Selective p38γ MAPK Inhibition Reduces Pathological Tau Phosphorylation in Alzhe

ATF4-DDIT3 stress signaling indirectly represses MAPT transcription during prote

HSF1 reprioritizes transcription and suppresses MAPT while restoring proteostasi

Tau-Independent Microtubule Stabilization via MAP6 Enhancement

REST-like neuronal silencing programs suppress MAPT in severe proteostatic stres

CX3CR1 PET with Nano-bodies for Microglial Surveillance State Mapping

Astrocyte CD38-erk Mapk signaling controls mitochondrial transfer to neurons via

AD fine-mapping identifies causal variants in microglia-specific enhancers with

CREB-Mediated Differential CD55/CD46 Expression Creates Activity-Dependent Compl

CREB-Mediated Differential CD55/CD46 Expression Creates Activity-Dependent Compl

MAP

Understanding Entity Pages

Summary

Wiki Pages (21)

Cerebral Autoregulation in Neurodegeneration

BIIB080 (MAPTRx) Antisense Oligonucleotide for Alzheimer's Disease

MAPK9 Gene

MAPK/ERK Signaling Pathway in Neurodegeneration

MAP1LC3A Gene

MAPT→Tau→Aggregation→PSP Causal Chain

MAP2K5

MAP6 Gene

JNK/p38 MAPK Signaling Pathway in Neurodegeneration

MAP3K6 Gene

BIIB080 (MAPTRx)

MAP3K4 — Mitogen-Activated Protein Kinase Kinase Kinase 4

MAP2K2 Gene

MAP2K3 Protein (MEK3)

Tau-MAPT-Tubulin Assembly

BIIB080 (MAPTRx) ASO Therapy for PSP

JNK/p38 MAPK Inhibitor Companies for Parkinson's Disease

MAP2K7

MAPT - Microtubule-Associated Protein Tau

MAP3K3 Gene

MAP3K5 — Mitogen-Activated Protein Kinase Kinase Kinase 5

Pathway Diagram

Outgoing (55)

Incoming (36)

Targeting Hypotheses (23)

Mentioning Analyses (3)

Which specific transcription factors mediate MAPT suppression during proteostati

Proteomics Differential Expression in AD CSF and Brain Tissue

Cas13 gRNA Design for Silencing MAPT (Tau) Transcripts in Alzheimer's Disease

Experiments (2)

Related Papers (11)

Debates (5)

Which specific transcription factors mediate MAPT suppression during proteostati

Can optimized Cas13 guide RNAs selectively silence pathogenic MAPT splice varian

Which proteins are differentially expressed in AD CSF and brain tissue, and do t

Is a 12-protein CSF panel superior to existing plasma p-tau217 for clinical AD p

Is Cas13-based 4R-tau silencing feasible given collateral cleavage risks in post

Related Research

DLK MAPK Pathway Inhibition to Block Tau-Induced Neurotoxicity Without Directly

Rutin stabilizes a non-nucleating tau conformer through direct MAPT repeat-domai

Selective p38γ MAPK Inhibition Reduces Pathological Tau Phosphorylation in Alzhe

ATF4-DDIT3 stress signaling indirectly represses MAPT transcription during prote

HSF1 reprioritizes transcription and suppresses MAPT while restoring proteostasi

Tau-Independent Microtubule Stabilization via MAP6 Enhancement

REST-like neuronal silencing programs suppress MAPT in severe proteostatic stres

CX3CR1 PET with Nano-bodies for Microglial Surveillance State Mapping

Astrocyte CD38-erk Mapk signaling controls mitochondrial transfer to neurons via

AD fine-mapping identifies causal variants in microglia-specific enhancers with

CREB-Mediated Differential CD55/CD46 Expression Creates Activity-Dependent Compl

CREB-Mediated Differential CD55/CD46 Expression Creates Activity-Dependent Compl